MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
14.15
+0.06 (0.43%)
Oct 14, 2025, 4:00 PM EDT - Market closed
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
64.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INKT News
- 15 days ago - MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors - GlobeNewsWire
- 19 days ago - MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA - GlobeNewsWire
- 26 days ago - MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development - GlobeNewsWire
- 2 months ago - MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results - GlobeNewsWire
- 2 months ago - MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewsWire
- 3 months ago - MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - GlobeNewsWire
- 3 months ago - Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? - Benzinga